secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016868
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q2 net loss $27M; NKX101 AML 60% CR, NKX019 NHL 50% CR
-------------------------------------------------------------

- Q2 2022 net loss $27.0M ($0.61/share); cash & investments $415.0M, sufficient into 2025.
- NKX101 Phase 1: 3/5 AML patients at higher dose achieved CR (60%); 2 of 3 MRD-negative.
- NKX019 Phase 1: 3/6 NHL patients at higher dose achieved CR (50%); included DLBCL and MCL.
- Raised ~$215.6M net from public offering in April 2022; lease amendments add $15M tenant improvements.
- Promoted leaders: Dr. Brandenberger to CTO, Yvonne Li to CAO, Dr. Shook to VP Clinical Dev.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022016868/0000950170-22-016868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022016868/nktx-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer